Dianthus Therapeutics (NASDAQ:DNTH) versus OSR (NASDAQ:OSRH) Head to Head Review

OSR (NASDAQ:OSRH) and Dianthus Therapeutics (NASDAQ:DNTH) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership and valuation.

Risk & Volatility

OSR has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500.

Profitability

This table compares OSR and Dianthus Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OSR	-593.15%	-8.36%	-6.24%
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%

Valuation & Earnings

This table compares OSR and Dianthus Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OSR	$1.81 million	5.38	-$27.06 million	($0.37)	-0.75
Dianthus Therapeutics	$2.04 million	2,977.37	-$162.34 million	($4.15)	-26.77

OSR has higher earnings, but lower revenue than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than OSR, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

55.3% of OSR shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 36.9% of OSR shares are owned by company insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for OSR and Dianthus Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OSR	1	0	0	0	1.00
Dianthus Therapeutics	1	0	12	1	2.93

Dianthus Therapeutics has a consensus target price of $124.27, suggesting a potential upside of 11.86%. Given Dianthus Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Dianthus Therapeutics is more favorable than OSR.

Summary

OSR beats Dianthus Therapeutics on 8 of the 15 factors compared between the two stocks.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.